|
|
 Previous Article | Table of Contents | Next Article 
BAVC regimen and autologous bone marrow transplantation in patients with
acute myelogenous leukemia in second remission
G Meloni, P De Fabritiis, MC Petti and F Mandelli
Department of Biopathology, University La Sapienza, Rome, Italy.
Twenty-one acute myelogenous leukemia (AML) patients were submitted in
second remission (II CR) to BAVC conditioning regimen followed by unpurged
ABMT. Transplant was done after a median of 2 months from II CR (range, 1
to 13). Median first remission (I CR) duration was 16 months (range, 1-35).
Conditioning regimen was well tolerated, with no major extra-medullary
toxicity. One patient died during aplasia from fungal sepsis. Of the 20
evaluable patients, nine relapsed after a median time of 6 months (range, 2
to 18). Eleven patients are in continuous complete remission (CCR) after a
median follow-up of 40 months (range, 24 to 63). The duration of II CR has
exceeded the duration of I CR in all patients in CCR. Projected probability
of disease-free survival is 52% at 63 months.
Volume 75,
Issue 12,
pp. 2282-2285,
06/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
X. Thomas, S. Suciu, B. Rio, G. Leone, G. Broccia, G. Fillet, U. Jehn, W. Feremans, G. Meloni, M. Vignetti, et al.
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61 70 years: results of the prospective EORTC GIMEMA AML 13 study
Haematologica,
March 1, 2007;
92(3):
389 - 396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Locatelli, M. Labopin, J. Ortega, G. Meloni, G. Dini, C. Messina, I. Yaniv, F. Fagioli, V. Castel, P. J. Shaw, et al.
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission
Blood,
February 15, 2003;
101(4):
1611 - 1619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. L. Coco, D. Diverio, G. Avvisati, M. C. Petti, G. Meloni, E. M. Pogliani, A. Biondi, G. Rossi, C. Carlo-Stella, C. Selleri, et al.
Therapy of Molecular Relapse in Acute Promyelocytic Leukemia
Blood,
October 1, 1999;
94(7):
2225 - 2229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Harousseau, J.-Y. Cahn, B. Pignon, F. Witz, N. Milpied, M. Delain, B. Lioure, T. Lamy, B. Desablens, F. Guilhot, et al.
Comparison of Autologous Bone Marrow Transplantation and Intensive Chemotherapy as Postremission Therapy in Adult Acute Myeloid Leukemia
Blood,
October 15, 1997;
90(8):
2978 - 2986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Meloni, D. Diverio, M. Vignetti, G. Avvisati, S. Capria, M. C. Petti, F. Mandelli, and F. Lo Coco
Autologous Bone Marrow Transplantation for Acute Promyelocytic Leukemia in Second Remission: Prognostic Relevance of Pretransplant Minimal Residual Disease Assessment by Reverse-Transcription Polymerase Chain Reaction of the PML/RARalpha Fusion Gene
Blood,
August 1, 1997;
90(3):
1321 - 1325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Meloni, S. Capria, M. Vignetti, F. Mandelli, and V. Modena
Blast Crisis of Chronic Myelogenous Leukemia in Long-Lasting Systemic Lupus Erythematosus: Regression of Both Diseases After Autologous Bone Marrow Transplantation
Blood,
June 15, 1997;
89(12):
4659 - 4659.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Imrie, K. Dicke, and A Keating
Autologous bone marrow transplantation for acute myeloid leukemia
Stem Cells,
January 1, 1996;
14(1):
69 - 78.
[Abstract]
|
|
|
|
|
